Anand Rathi Recommends 'BUY' on Global Health, Sets Target at Rs 1450

• Global Health's Q3FY26 revenue rose 19% YoY, surpassing estimates, but EBITDA declined 10% and missed projections.
• PAT fell 8% YoY, while Adjusted PAT plunged 33.5% due to a labor code adjustment.
• ARPOB increased 10% YoY to Rs 67,361, but overall occupancy dropped to 59% from 64% in Q3FY25.
• Company announced a 400-bed hospital in South Delhi with DLF; Medanta added 144 beds in Q3, totaling 3,579 beds.
• Anand Rathi maintains 'BUY' rating with a revised target price of Rs 1,450, projecting strong CAGR for revenue, EBITDA, and PAT.